DekaBank Deutsche Girozentrale lessened its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 1.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 70,325 shares of the biotechnology company’s stock after selling 1,274 shares during the quarter. DekaBank Deutsche Girozentrale owned approximately 0.16% of United Therapeutics Corporation worth $9,346,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in United Therapeutics Corporation during the 3rd quarter worth $156,000. Eagle Global Advisors LLC acquired a new stake in United Therapeutics Corporation during the 2nd quarter worth $206,000. Toronto Dominion Bank boosted its stake in United Therapeutics Corporation by 244.7% during the 3rd quarter. Toronto Dominion Bank now owns 1,903 shares of the biotechnology company’s stock worth $223,000 after purchasing an additional 1,351 shares during the last quarter. TLP Group LLC acquired a new stake in United Therapeutics Corporation during the 2nd quarter worth $246,000. Finally, HPM Partners LLC boosted its stake in United Therapeutics Corporation by 0.8% during the 2nd quarter. HPM Partners LLC now owns 1,981 shares of the biotechnology company’s stock worth $257,000 after purchasing an additional 15 shares during the last quarter.

In related news, Director Christopher Causey sold 580 shares of the business’s stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $134.48, for a total value of $77,998.40. Following the sale, the director now directly owns 3,295 shares in the company, valued at approximately $443,111.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Martine A. Rothblatt sold 1,238 shares of the business’s stock in a transaction dated Thursday, August 24th. The shares were sold at an average price of $130.65, for a total transaction of $161,744.70. Following the completion of the sale, the chief executive officer now owns 2,307 shares in the company, valued at $301,409.55. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 23,879 shares of company stock worth $2,926,931. 7.80% of the stock is owned by insiders.

COPYRIGHT VIOLATION WARNING: “DekaBank Deutsche Girozentrale Sells 1,274 Shares of United Therapeutics Corporation (UTHR)” was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://www.watchlistnews.com/dekabank-deutsche-girozentrale-sells-1274-shares-of-united-therapeutics-corporation-uthr/1711814.html.

Shares of United Therapeutics Corporation (UTHR) traded up $1.40 on Friday, reaching $123.02. 297,623 shares of the company traded hands, compared to its average volume of 383,757. The stock has a market cap of $5,320.00, a price-to-earnings ratio of 10.46 and a beta of 1.38. United Therapeutics Corporation has a 12-month low of $112.01 and a 12-month high of $169.89.

United Therapeutics Corporation (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported $6.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.01 by $2.26. The firm had revenue of $445.50 million for the quarter, compared to analyst estimates of $426.43 million. United Therapeutics Corporation had a net margin of 30.50% and a return on equity of 26.24%. United Therapeutics Corporation’s revenue was up 9.1% on a year-over-year basis. During the same period in the previous year, the firm earned $4.23 EPS. equities analysts predict that United Therapeutics Corporation will post 11.92 EPS for the current year.

UTHR has been the topic of several recent research reports. ValuEngine cut shares of United Therapeutics Corporation from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 28th. BidaskClub cut shares of United Therapeutics Corporation from a “hold” rating to a “sell” rating in a research note on Monday, July 31st. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating on shares of United Therapeutics Corporation in a research note on Friday, September 8th. Zacks Investment Research cut shares of United Therapeutics Corporation from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 3rd. Finally, TheStreet cut shares of United Therapeutics Corporation from a “b-” rating to a “c” rating in a research note on Friday, September 29th. Five analysts have rated the stock with a sell rating, seven have given a hold rating and three have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $132.82.

United Therapeutics Corporation Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR).

Institutional Ownership by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.